As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role ...

Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...

In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...

Hollings researchers will develop AI-driven tools to better match cancer patients to marketed therapies and clinical trials.

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

The firm is also studying PTG-007 in patients with early-stage type 1 diabetes, but is looking for a partner for the pivotal trial.

The pharmaceutical distributor has launched InspiroGene, a business unit offering logistics and other support for ...

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

A 31-year-old woman with stage IV breast cancer learns a test ordered more than a year before her diagnosis detected a TP53 ...

The firm will track the activity of the triplet broadly in AML patients, including in those with FLT3, NRAS, and TP53 mutations.

The firm will test the activity of NEU-411 in patients with Parkinson's caused by LRRK2 mutations or whose disease is influenced by LRRK2 overactivity.